GlassScriptPhysician profile
Aliya Rathore
NPI 1093757262
$3,600.20
in general payments reported to CMS, 2019-2025
24 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $385 · 2021: $401 · 2022: $535 · 2023: $661 · 2024: $537 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $905.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $397.89 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $303.94 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $287.85 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.23 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $242.74 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $190.39 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $167.68 | 2021-2025 | |
| Dexcom, INC. | $139.98 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $111.17 | 2022-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $110.42 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $80.61 | 2021-2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $70.55 | 2019 | |
| Pfizer INC. | $52.06 | 2023-2024 | |
| Corcept Therapeutics | $51.57 | 2025 | Korlym |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51.27 | 2022-2024 | |
| Amarin Pharma, INC. | $44.51 | 2020 | |
| Medtronic, INC. | $35.39 | 2024 | Intellis Adaptivestim, Venaseal |
| Otsuka America Pharmaceutical, INC. | $19.98 | 2023 | Rexulti |
| Philips North America LLC | $17.72 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.08 | 2022 | |
| Genentech USA, INC. | $16.90 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.18 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $13.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliya Rathore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.